Search results
AstraZeneca to build $1.5 bln cancer drug facility in Singapore
Medical Xpress· 5 days agoBritish pharmaceutical giant AstraZeneca said Monday that it planned to build a $1.5 billion plant...
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Benzinga· 5 days agoA Delaware federal jury has determined that AstraZeneca Plc AZN must pay Pfizer Inc PFE $107.5...
AstraZeneca (LON:AZN) Earns “Buy” Rating from Shore Capital
ETF DAILY NEWS· 1 day agoShore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports ...
Pfizer's $1.5B cuts; Biogen's $1.15B buyout; AstraZeneca's $80B ambition; RNA startup merger; and...
Endpoints News· 6 hours agoWant this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. Whether you will be in San Diego for BIO, we hope you will join ...
SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca
BioPharma Dive via Yahoo Finance· 3 days agoA new obesity drug developer from investment firm Versant Ventures is starting up with a deal to...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 4 days agoDive Brief: AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a slate of...
AstraZeneca aims to deliver $80 billion in total revenue by 2030
KFGO· 4 days ago(Reuters) -AstraZeneca said on Tuesday it expects to deliver $80 billion in total revenue by 2030,...
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient...
Benzinga via Yahoo Finance· 5 days agoSunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase...
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
Zacks via Yahoo Finance· 3 days agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is...
AstraZeneca PLC (NASDAQ:AZN) Receives $81.00 Average Price Target from Analysts
ETF DAILY NEWS· 7 days agoShares of AstraZeneca PLC (NASDAQ:AZN – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company ...